Integrase strand transfer inhibitors resistance-associated mutations in HIV-infected pregnant women.

D Cecchini, J Sfalcin, I Zapiola, A Gomez, S Fernandez-Giuliano, C Rodriguez, L Mammana, A Seravalle, F Fay, M C Torroija, G Bugarín, M B Bouzas
{"title":"Integrase strand transfer inhibitors resistance-associated mutations in HIV-infected pregnant women.","authors":"D Cecchini, J Sfalcin, I Zapiola, A Gomez, S Fernandez-Giuliano, C Rodriguez, L Mammana, A Seravalle, F Fay, M C Torroija, G Bugarín, M B Bouzas","doi":"10.37201/req/074.2024","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To date, no data exist regarding the prevalence of integrase inhibitor (INSTI) resistance-associated mutations (HIVDRM) in HIV-infected pregnant women (HPW) in Latin America. We describe the prevalence and transmissibility of integrase HIVDRM in a historical cohort of INSTI-naïve HPW from Argentina (n=56) with Next Generation Sequencing (NGS).</p><p><strong>Methods: </strong>Bioinformatics analysis was performed by HyDRA software for 20%, 10%, 5%, 2%, and 1% sensitivity thresholds. We calculated the mutational viral load for each INSTI-HIVDRM, considering those with >1000 c/mL as of high risk of transmissibility.</p><p><strong>Results: </strong>The predominant HIV subtype was BF (78.5%). Major HIVDRM were not detected with the population sequencing 20% filter. With a 1% threshold, the prevalence increased to 8.9%; Y143C/S, E92G, E138K, and T66I mutations were found. The median (range) mutational load (expressed in c/mL) was: 355 (50.2-11705); with only 1 case >1000 c/mL Accessory mutations (G163R/K, T97A) were detected mostly with a 20% sensitivity threshold with an overall prevalence of 23.2%; the median (IQR) mutational load was: 23929 (4009-63158) c/mL; all of them above 1000 c/mL.</p><p><strong>Conclusions: </strong>Our results show evidence of the presence of major INSTI-HIVDRM as aleatory mutations and a high frequency of accessory mutations with potential transmissibility in HPW.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"479-485"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11578435/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37201/req/074.2024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/4 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To date, no data exist regarding the prevalence of integrase inhibitor (INSTI) resistance-associated mutations (HIVDRM) in HIV-infected pregnant women (HPW) in Latin America. We describe the prevalence and transmissibility of integrase HIVDRM in a historical cohort of INSTI-naïve HPW from Argentina (n=56) with Next Generation Sequencing (NGS).

Methods: Bioinformatics analysis was performed by HyDRA software for 20%, 10%, 5%, 2%, and 1% sensitivity thresholds. We calculated the mutational viral load for each INSTI-HIVDRM, considering those with >1000 c/mL as of high risk of transmissibility.

Results: The predominant HIV subtype was BF (78.5%). Major HIVDRM were not detected with the population sequencing 20% filter. With a 1% threshold, the prevalence increased to 8.9%; Y143C/S, E92G, E138K, and T66I mutations were found. The median (range) mutational load (expressed in c/mL) was: 355 (50.2-11705); with only 1 case >1000 c/mL Accessory mutations (G163R/K, T97A) were detected mostly with a 20% sensitivity threshold with an overall prevalence of 23.2%; the median (IQR) mutational load was: 23929 (4009-63158) c/mL; all of them above 1000 c/mL.

Conclusions: Our results show evidence of the presence of major INSTI-HIVDRM as aleatory mutations and a high frequency of accessory mutations with potential transmissibility in HPW.

感染艾滋病毒的孕妇体内与整合酶链转移抑制剂耐药性相关的突变。
目的:迄今为止,还没有关于拉丁美洲感染艾滋病毒的孕妇(HPW)中整合酶抑制剂(INSTI)耐药性相关突变(HIVDRM)流行率的数据。我们利用新一代测序技术(NGS)描述了阿根廷 INSTI 耐药 HPW 历史队列(n=56)中整合酶 HIVDRM 的流行率和传播性:使用 HyDRA 软件对 20%、10%、5%、2% 和 1% 的敏感性阈值进行生物信息学分析。我们计算了每种 INSTI-HIVDRM 的突变病毒载量,将大于 1000 c/mL 的病毒视为高传播风险病毒:主要的 HIV 亚型是 BF(78.5%)。使用人群测序 20% 过滤器未检测到主要的 HIVDRM。以 1%为阈值,发病率增至 8.9%;发现了 Y143C/S、E92G、E138K 和 T66I 突变。突变负荷(以 c/mL 表示)的中位数(范围)为辅助突变(G163R/K、T97A)的检测灵敏度阈值大多为 20%,总发生率为 23.2%;突变负荷中位数(IQR)为:23929 (4009-63158) c/mL;所有突变负荷均高于 1000 c/mL:我们的研究结果表明,在 HPW 中存在主要的 INSTI-HIVDRM 变异和高频率的具有潜在传播性的附属变异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信